Undisclosed Placebo Trials in Clinical Practice: Undercover Beneficence or Unwarranted Deception?
Narrative Inquiry in Bioethics · 2023
DOI: 10.1353/nib.2023.0017 ↗Kurz gefasst
Fallbericht in der Zeitschrift Narrative Inquiry in Bioethics, 2023. Verfasst von Daniel Edward Callies. Hauptthemen laut MEDLINE: Beneficence, Deception. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
A placebo is an intervention that is believed to lack specific pharmacological or physiological efficacy for a patient's condition. While placebo-controlled trials are considered the gold standard when it comes to researching and testing new pharmacological treatments, the use of placebos in clinical practice is more controversial. The focus of this case study is an undisclosed placebo trial used as an attempt to diagnose a patient's complex and unusual symptomology. In this case, the placebo was used not just as a treatment, but as a diagnostic intervention in order to determine the best course of treatment for a patient. Could the deceptive use of a placebo be justified in clinical practice on the grounds of beneficence?
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Callies, D. E. (2023). Undisclosed Placebo Trials in Clinical Practice: Undercover Beneficence or Unwarranted Deception?. Narrative Inquiry in Bioethics. https://doi.org/10.1353/nib.2023.0017
Vancouver
Callies DE. Undisclosed Placebo Trials in Clinical Practice: Undercover Beneficence or Unwarranted Deception?. Narrative Inquiry in Bioethics. 2023. doi:10.1353/nib.2023.0017
BibTeX
@article{Callies2023,
author = {Callies, Daniel Edward},
title = {Undisclosed Placebo Trials in Clinical Practice: Undercover Beneficence or Unwarranted Deception?},
journal = {Narrative Inquiry in Bioethics},
year = {2023},
doi = {10.1353/nib.2023.0017}
}
EUVIMED